Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)

Postema, Ernst J.; McEwan, Alexander; Riauka, Terence; Kumar, Piyush; Richmond, Dacia A.; Abrams, Douglas N.; Wiebe, Leonard I.

doi:10.1007/s00259-009-1154-5

Cited by 151 publications

(88 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reischl et al [165] , Piert et al [166] , Picchio et al [167] , Maier et al [168] , Tran et al [169] Barthel et al [187] Busk et al [170] , Mortensen et al [171] , Piert et al [166] , Tran et al [169] Barthel et al [187] Busk et al [170] , Busk et al [172] , Busk et al [173] , Busk et al [174] , Busk et al [175] , Graves et al [176] , Maier et al [168] , Solomon et al [177] NA Belloli et al [178] , Picchio et al [167] , Troost et al [179] , Valtorta et al [143] NA Sorger et al [57] , Piert et al [166] , Reischl et al [165] Rasey et al [188] Postema et al [180] , Bollineni et al [181] , Trinkaus et al [58] , Verwer et al [59] NA Grosu et al [182] , Souvatzoglou et al [183] , Schuetz et al [184] , Shi et al [106] , Mortensen et al [185] , Havelund et al [186] NA…”

Section: F]ef5mentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

Core tip:This review provides an overview of the current applications of positron emission tomography for hypoxia and perfusion imaging in lung cancer. Available PET tracers are discussed and the benefits of combined hypoxia and perfusion PET imaging are clarified. Hypoxia imaging could aid in selecting patients for hypoxia-specific treatment strategies. To achieve this, consensus about the optimal imaging protocol and quantification method is essential. Large clinical trials are needed to confirm the value of hypoxia imaging for improving patient care.Verwer EE, Boellaard R, van der Veldt AAM. Positron emission tomography to assess hypoxia and perfusion in lung cancer.

show abstract

Section: F]ef5mentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

show abstract

“…The radical anion appears to undergo additional reduction and binds to macromolecules, and thus the associated radiolabel is selectively retained in hypoxic cells. This under Figure 3) [7][8][9], [ [10][11][12][13] [15], which is a more hydrophilic nitroimidazole compound and shows rapid elimination of non-target tissues via excretion through the urinary pathway. [ (2,2,3,3,3-pentafluoropropyl) [14] are other known hypoxia imaging agents ( Figure 3) developed to improve the imaging performance by improving target to non-target ratio by increasing excretion rates.…”

Section: Introductionmentioning

confidence: 99%

Development of 68Ga-labeled multivalent nitroimidazole derivatives for hypoxia imaging

Seelam

Lee

et al. 2015

Bioorganic & Medicinal Chemistry

View full text Add to dashboard Cite

“…It is not easy to solve this dilemma between uptake time and contrast. Postema et al conducted a study of FAZA PET in 50 patients with a number of different malignant tumors, including seven glioblastoma patients [51]. Here images were acquired 2-3 h after injection, and the image quality was reported as good, but not superior to FMISO.…”

Section: Discussionmentioning

confidence: 99%

Hypoxia Imaging with 18F-FMISO PET for Brain Tumors

Hirata

Kobayashi

Tamaki

2016

Perspectives on Nuclear Medicine for Molecular Diagnosis and Integrated Therapy

View full text Add to dashboard Cite

Tumor hypoxia is an important object for imaging because hypoxia is associated with tumor aggressiveness and resistance to radiation therapy. Here, 18 Ffluoromisonidazole (FMISO) has been used for many years as the most commonly employed hypoxia imaging tracer. Unlike F-18 fluorodeoxyglucose (FDG), FMISO does not accumulate in normal brain tissue making it able to provide images of hypoxic brain tumors with high contrast. Clinical evidence has suggested that FMISO PET can predict patient prognosis and treatment response. Among gliomas of various grades (WHO 2007), it has been known that grade IV glioblastoma resides under severe hypoxia and is a cause of development of necrosis in the tumor. For this study we tested whether FMISO can distinguish the oxygen condition of glioblastomas and lower-grade gliomas. Twenty-three glioma patients underwent FMISO PET for the study. All the glioblastoma patients (N ¼ 14) showed high FMISO uptakes in the tumor, whereas none of the other patients (i.e., gliomas of grade III or lower, N ¼ 9) did, demonstrated by both qualitative and quantitative assessments. The data suggest that FMISO PET may be a useful tool to distinguish glioblastomas from lower-grade gliomas. Our results, however, were slightly different from previous investigations reporting that some lowergrade gliomas (e.g., grade III) showed positive FMISO uptake. Many of these acquired the FMISO PET images 2 h after the FMISO injection, while for the study here we waited 4 h to be able to collect hypoxia-specific signals rather than perfusion signals as FMISO clearance from plasma is slow due to its lipophilic nature. No optimum uptake time for FMISO has been established, and we directly compared the 2-h vs. the 4-h images with the same patients (N ¼ 17). At 2 h, the gray matter had significantly higher standardized uptake value (SUV) than the white matter, possibly due to different degrees of perfusion but not due to hypoxia. At 4 h, there were no differences between gray and white matter without any significant increase in the noise level measured by the coefficient of variation between the 2-h and the 4-h images. At 2 h, 6/8 (75 %) of glioblastoma patients showed higher uptakes in the tumor than in the surrounding brain tissue, whereas at 4 h this was the case for 8/8 (100 %). In addition, at 2 h, 3/4 (75 %) of patients with lower-grade gliomas showed moderate uptakes, while at 4 h none did (0/4 or 0 %). These data indicate that 4-h images are better than 2-h images for the purpose of glioma grading. In conclusion, we evaluated the diagnostic performance of FMISO PET for gliomas and suggest that FMISO PET may be able to assist in the diagnosis of glioblastomas when PET images are acquired at 4 h post injection.Keywords Hypoxia • 18 F-Fluoromisonidazole • Glioma • Glioblastoma IntroductionThis review article summarizes our recent studies with 18 F-fluoromisonidazole (FMISO) positron emission tomography (PET) applied to brain tumors [1,2]. A variety of tumors which can be divided into two categories develop ...

show abstract

Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)

Cited by 151 publications

References 20 publications

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Development of 68Ga-labeled multivalent nitroimidazole derivatives for hypoxia imaging

Hypoxia Imaging with 18F-FMISO PET for Brain Tumors

Contact Info

Product

Resources

About